Generate Biomedicines Inc.
GENB | NASDAQ
$14.46
-$1.31 (-8.31%)
At close: Oct 30, 2026, 4:00 PM ET
$14.42
-$0.04 (-0.28%)
Pre-market:
Nov 2, 2026, 8:18 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 |
|---|---|---|
Cash & Equivalents | 121.65M | 176.27M |
Short-Term Investments | 99.85M | 217.36M |
Long-Term Investments | n/a | n/a |
Other Long-Term Assets | 6.81M | 9.7M |
Receivables | n/a | 308K |
Inventory | n/a | n/a |
Other Current Assets | 12.87M | 13.56M |
Total Current Assets | 234.37M | 407.49M |
Property-Plant & Equipment | 89.01M | 101.07M |
Goodwill & Intangibles | n/a | n/a |
Total Long-Term Assets | 95.82M | 110.77M |
Total Assets | 330.18M | 518.26M |
Account Payables | 3.84M | 5.67M |
Deferred Revenue | 21.19M | 42.43M |
Short-Term Debt | n/a | n/a |
Other Current Liabilities | 16.43M | 15.78M |
Total Current Liabilities | 82.2M | 86.63M |
Long-Term Debt | n/a | n/a |
Other Long-Term Liabilities | 813.15M | 791.29M |
Total Long-Term Liabilities | 871.18M | 866.72M |
Total Liabilities | 953.38M | 953.35M |
Total Debt | 68.53M | 76.97M |
Book Value | -623.2M | -435.09M |
Book Value Per Share | -12.44 | -3.41 |
Common Stock | 50K | 50K |
Retained Earnings | -676.29M | -473.14M |
Comprehensive Income | 106K | 118K |
Shareholders Equity | -615.97M | -434.52M |
Total Investments | 99.85M | 217.36M |
Add to Watchlist
Select watchlists to add or remove GENB